Heineken warns weight-loss drugs like Ozempic may reduce beer drinking, urging pubs to adapt or lose revenue.

Heineken has privately warned British pubs that the rise of GLP-1 weight-loss drugs such as Ozempic and Wegovy could reduce customers' desire to drink alcohol, especially multi-pint rounds, which are key to pub revenue. The company suggests promoting smaller servings and low- or no-alcohol drinks to adapt. Despite this, Heineken's overall sales and profits grew in early 2026, though the trend poses a risk to traditional beer consumption patterns. Upcoming quarterly reports from Heineken and Anheuser-Busch InBev will be closely watched for volume impacts as the drugs become more common.

Anheuser-Busch InBev (BUD) shares are trading near their 52-week high at USD 84.26 as of Oct 24, 2026 22:41 WIB, down slightly by 1.44% on the day. This price contrasts with the 52-week low of USD 60.01, showing resilience despite concerns about the impact of GLP-1 weight-loss drugs on beer consumption. The stock's dividend yield stands at 1.6%, reflecting ongoing shareholder returns amid evolving market dynamics.